LIAN LIANBIO

LianBio to Participate in Upcoming Investor and Industry Events

LianBio to Participate in Upcoming Investor and Industry Events

SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the following upcoming investor and industry conferences:

  • BioCentury-BayHelix East-West Biopharma Summit – November 14-18, 2022
    • Panel: BioCentury Scene Setter Report: Does East-West Matter? – November 15 at 9:00 am PT
    • Panel: Capital Session I: Capital Markets Showcase Workshop: A Mountain of Dry Powder – November 16, 2022 at 1:15 pm PT
    • Company Presentation – November 15, 2022 at 2:48 pm PT
    • 1:1 Meetings
  • Goldman Sachs Asia Pacific Healthcare Forum – November 15-18, 2022
    • Panel: Biotech Reshaping – Revisit China and Global Strategy – November 15, 2022 at 9:00 am HKT
    • 1:1 Meetings
  • Jefferies London Healthcare Conference – November 15-17, 2022
    • Fireside Chat – November 16, 2022 at 10:55 am GMT
    • 1:1 Meetings

A live audio webcast of the Jefferies London Healthcare Conference will be accessible from the Investors section of LianBio’s website at with a replay available following the live event. To learn more about the BioCentry-BayHelix event, visit the event website at .

About LianBio

LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit .

For investor inquiries, please contact:

Elizabeth Anderson, VP Communications and Investor Relations

E:

T:

For media inquiries, please contact:

Josh Xu, Director of Communications

E: 

T:  15

Katherine Smith, Evoke Canale

E: 

T: 



EN
10/11/2022

Underlying

LIANLIANBIO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LIANBIO

 PRESS RELEASE
Free
LIAN LIANBIO

LianBio Announces Voluntarily Delisting from Nasdaq

LianBio Announces Voluntarily Delisting from Nasdaq SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) (“LianBio” or the “Company”), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. (“Nasdaq”) of its intent to delist the Company’s American Depositary Shares (“ADSs”), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a ...

February 28, 2024 1 EN
 PRESS RELEASE
Free
LIAN LIANBIO

LianBio Announces Completion of Strategic Review

LianBio Announces Completion of Strategic Review LianBio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from Nasdaq and issuance of special cash dividend SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) (“LianBio” or the “Company”), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company’s Board of Directors (the “Board”) had completed its comprehensive strategic review of the Compa...

February 13, 2024 1 EN
 PRESS RELEASE
Free
LIAN LIANBIO

LianBio Announces Departure of Chief Financial Officer

LianBio Announces Departure of Chief Financial Officer SHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio to pursue other opportunities, effective December 19, 2023. In connection with her departure, the LianBio Board of Directors has appointed Ehong (Maggie) Gu, current VP, Head of Global Finance, as Interim Chief Financial Officer. “We are gra...

December 20, 2023 1 EN
 PRESS RELEASE
Free
LIAN LIANBIO

LianBio Announces Departure of Chief Executive Officer

LianBio Announces Departure of Chief Executive Officer SHANGHAI, China and PRINCETON, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yizhe Wang, Ph.D., Chief Executive Officer has resigned from LianBio to pursue other opportunities. In connection with his departure, the LianBio Board of Directors has appointed Adam Stone, Chief Investment Officer of Perceptive Advisors and member of the LianBio Board of Directors as Interim Chief Exe...

December 19, 2023 1 EN
 PRESS RELEASE
Free
LIAN LIANBIO

LianBio’s Board of Directors Unanimously Determines not to Pursue Unso...

LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences SHANGHAI, China and PRINCETON, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that its Board of Directors (the “Board”) unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, LLC to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing th...

December 6, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch